Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils

Launched by MEDICAL UNIVERSITY INNSBRUCK · Sep 2, 2020

Keywords

ClinConnect Summary

This clinical trial, based at the University Hospital of Innsbruck, is focused on understanding and treating conditions that involve high levels of a type of white blood cell called eosinophils, particularly in the lungs. The study aims to create a registry of patients with various eosinophilic respiratory diseases, such as eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). Researchers will gather important health information from these patients, including blood tests and lung function assessments, to learn more about how these conditions develop and how they can be treated more effectively.

To be eligible for the study, participants must be at least 18 years old, have a documented high eosinophil count in their blood, and show signs of lung damage caused by eosinophils. The good news is that joining the study doesn’t require any extra tests or procedures beyond what patients would typically undergo for their condition, so there’s no added risk for them. This research hopes to provide new insights that could lead to better treatments for people with these eosinophilic lung diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age ≥ 18 years
• • documented blood eosinophilia ≥ 300 cells/µl
• • present tissue damage of the respiratory tract caused by eosinophils
• Exclusion Criteria:
• • age \< 18 years
• • pregnancy
• • dementia
• • incapacitated patients